Driehaus Capital Management LLC Sells 4,807 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Driehaus Capital Management LLC decreased its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 1.1% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 437,123 shares of the company’s stock after selling 4,807 shares during the period. Driehaus Capital Management LLC owned about 0.58% of IDEAYA Biosciences worth $15,347,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Scientech Research LLC raised its stake in IDEAYA Biosciences by 362.3% in the second quarter. Scientech Research LLC now owns 27,708 shares of the company’s stock valued at $973,000 after buying an additional 21,714 shares during the period. Millennium Management LLC increased its stake in shares of IDEAYA Biosciences by 87.1% during the second quarter. Millennium Management LLC now owns 258,606 shares of the company’s stock worth $9,080,000 after purchasing an additional 120,395 shares during the period. D. E. Shaw & Co. Inc. increased its stake in shares of IDEAYA Biosciences by 34.4% during the second quarter. D. E. Shaw & Co. Inc. now owns 884,538 shares of the company’s stock worth $31,056,000 after purchasing an additional 226,514 shares during the period. Squarepoint Ops LLC increased its stake in shares of IDEAYA Biosciences by 127.1% during the second quarter. Squarepoint Ops LLC now owns 100,502 shares of the company’s stock worth $3,529,000 after purchasing an additional 56,256 shares during the period. Finally, Samlyn Capital LLC increased its stake in shares of IDEAYA Biosciences by 27.1% during the second quarter. Samlyn Capital LLC now owns 611,820 shares of the company’s stock worth $21,481,000 after purchasing an additional 130,595 shares during the period. Institutional investors own 98.29% of the company’s stock.

IDEAYA Biosciences Stock Performance

Shares of IDYA stock opened at $30.80 on Friday. The stock’s fifty day moving average price is $37.92 and its two-hundred day moving average price is $39.23. The company has a market cap of $2.33 billion, a PE ratio of -15.32 and a beta of 0.84. IDEAYA Biosciences, Inc. has a fifty-two week low of $23.41 and a fifty-two week high of $47.74.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its earnings results on Tuesday, August 6th. The company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.14). IDEAYA Biosciences had a negative net margin of 483.05% and a negative return on equity of 20.52%. During the same period last year, the company posted ($0.50) earnings per share. On average, equities analysts predict that IDEAYA Biosciences, Inc. will post -2.51 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. Wedbush lowered their target price on IDEAYA Biosciences from $54.00 to $52.00 and set an “outperform” rating on the stock in a research note on Tuesday, September 24th. Lifesci Capital upgraded IDEAYA Biosciences to a “strong-buy” rating in a research note on Monday, July 29th. Stifel Nicolaus increased their target price on IDEAYA Biosciences from $63.00 to $68.00 and gave the stock a “buy” rating in a research note on Tuesday, September 10th. Oppenheimer lowered their price objective on IDEAYA Biosciences from $60.00 to $53.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 7th. Finally, BTIG Research raised their price objective on IDEAYA Biosciences from $55.00 to $62.00 and gave the stock a “buy” rating in a research note on Tuesday, July 9th. Twelve analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, IDEAYA Biosciences has a consensus rating of “Buy” and a consensus target price of $56.00.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.